Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting
文献类型：期刊论文
| 作者 | Zhai HengBo2; Liu Jun2; Dong ZhiChao2; Wang DongXia2; Zhang Bo2 |
| 刊名 | Chinese Medical Journal
 |
| 出版日期 | 2017 |
| 卷号 | 130期号:12页码:1418-1423 |
| 关键词 | Antithrombotic Therapy Medicine R Atrial Fibrillation Coronary Artery Disease Percutaneous Coronary Intervention Prognosis |
| ISSN号 | 0366-6999 |
| 其他题名 | Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting |
| 英文摘要 | Background: It is currently believed that triple oral antithrombotic therapy in patients with atrial fibrillation (AF) after percutaneous coronary intervention (PCI) should be recommended if there are no contraindications. However, selecting triple therapy for AF patients undergoing PCI is still challenging when bleeding risk is considered. This study aimed to investigate the current use of oral anticoagulants (Vitamin K antagonists VKA) and perform prognostic analysis in real-world patients with AF undergoing coronary stenting. Methods: A total of 276 consecutive coronary artery disease (CAD) patients with or without AF undergoing coronary stenting were retrospectively evaluated and analyzed. The univariate and multivariate analyses were conducted to explore the current use of VKA and prognosis of patients with AF undergoing coronary stenting. The primary end-point was composite of all-cause death, nonfatal recurrent myocardial infarction, stroke, serious bleeding events, unplanned repeat revascularization, and worsening heart failure at 12-month follow-up after coronary stenting. Results: AF patients undergoing coronary stenting have more clinical concomitant diseases. Only 9.0% AF patients after coronary stenting received triple antithrombotic therapy (VKA, aspirin, and clopidogrel) at discharge. AF was independently associated with increased risk of the 12-month composite end-points (relative risk = 5.732, 95% confidence interval 1.786–18.396, P = 0.003). Conclusions: In real-life AF patients undergoing coronary stenting, guideline-recommended VKA was less used. AF patients had adjusted worse prognosis during 12-month follow-up after discharge. It is of utmost importance to improve the current status of oral anticoagulants use. |
| 资助项目 | [Health and Family Planning Commission of Liaoning, China] ; [Science and Technology Program of Dalian, China] |
| 语种 | 英语 |
| CSCD记录号 | CSCD:6009463 |
| 源URL | [http://ir.imr.ac.cn/handle/321006/157619]  |
| 专题 | 金属研究所_中国科学院金属研究所 |
| 作者单位 | 1.中国科学院金属研究所 2.Dalian Med University, Affiliated Hosp 1, Dept Cardiol, Dalian 116011, Liaoning, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhai HengBo,Liu Jun,Dong ZhiChao,et al. Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting[J]. Chinese Medical Journal,2017,130(12):1418-1423. |
| APA | Zhai HengBo,Liu Jun,Dong ZhiChao,Wang DongXia,&Zhang Bo.(2017).Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting.Chinese Medical Journal,130(12),1418-1423. |
| MLA | Zhai HengBo,et al."Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting".Chinese Medical Journal 130.12(2017):1418-1423. |
入库方式： OAI收割
来源：金属研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。